Ocriplasmin: 5 agencies, 2013–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 6.2 years, from 31 May 2013 at AWMSG (Wales) to 2019 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2014, recommended by 2019, after a resubmission.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for ocriplasmin, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2019; on this evidence the file is dormant.
3 distinct indication wordings are recorded for ocriplasmin by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 7 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess ocriplasmin, on 31 May 2013; G-BA (Germany) did not open a file until 4 Apr 2019 — a wide spread of 5.9 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2014 alone.
PBAC (Australia) is the only agency to have returned to ocriplasmin, recording 3 separate entries.
Coverage is narrow: only 5 of the 18 agencies here have assessed ocriplasmin.
The full ledger for ocriplasmin reads 3 recommended, 1 restricted, 1 withdrawn and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2019 | Vitreomacular traction syndrome (VTS) | The PBAC recommended the Authority Required listing of the new form of ocriplasmin for the… | source |
| G-BA (Germany) | 4 Apr 2019 | Jetrea — benefit assessment §35a | added benefit: minor (hint) | source |
| TLV (Sweden) | 22 Dec 2014 | Jetrea ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| SMC (Scotland) | 11 Aug 2014 | In adults for the treatment of vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns. | withdrawn | source |
| AWMSG (Wales) | 31 May 2013 | Treatment of vitreomacular traction (VMT) in adults, including when associated with macular hole of diameter less than o… | excluded, NICE appraised | source |
2 further decisions for ocriplasmin, across 1 agency, are not shown here.
Related molecules
- pegcetacoplan — same ATC class S01X — Ophthalmologicals
- ciclosporin — same ATC class S01X — Ophthalmologicals
- mercaptamine — same ATC class S01X — Ophthalmologicals
- voretigene neparvovec — same ATC class S01X — Ophthalmologicals
- cenegermin — same ATC class S01X — Ophthalmologicals
- alirocumab — also decided by G-BA in 2019Q2
Coverage: 7 decisions for ocriplasmin from 5 agencies, 2013 to 2019. Data to 7 Sep 2026. ATC class S01X — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.